Clinical Scorecard: What Does Democratic Control of Congress Mean for Global Health?

At a Glance

Key Highlights

• Democratic congressional control may bring more pointed oversight of the America First Global Health Strategy, bilateral MOUs, and the consequences of USAID’s closure.
• Congress may use more forceful appropriations language to specify how global health funds must be used; the administration’s response remains uncertain.
• Policy questions include responsible program transitions, monitoring systems, PEPFAR’s future role, country financing, and support for vulnerable populations.
• Expanded pooled procurement and U.S. multilateral engagement are among the approaches raised for consideration.
• The future of bipartisan cooperation remains uncertain.

Guideline-Based Recommendations

Diagnosis

Management

• Congress may increase oversight through hearings, investigations, document requests, reporting requirements, and appropriations provisions.
• Congress may seek to specify how appropriated global health funds are used; whether it would pursue legal action if the administration rejects such efforts is uncertain.
• Questions raised for consideration include responsible transitions and sustainability, PEPFAR’s future role, support for vulnerable populations, bilateral assistance during financial vulnerability or crises, and pooled procurement.

Monitoring & Follow-up

• The article identifies a need for data, transparency, early-warning indicators, metrics, and monitoring systems to assess program transitions and progress.
• Information gaps concerning bilateral MOUs and implementation plans have constrained monitoring of services, programs, and health outcomes.

Risks

• The administration may disregard congressional demands, intensify its current course, or seek cooperation; its response is uncertain.
• Executive authority, agency leadership changes, and uncertainty about bipartisanship may affect global health programs and policy.
• The administration rescinded some appropriated funds and redirected others from their originally designated purposes.

Patient & Prescribing Data

Not applicable; the article concerns U.S. global health policy and populations reached by U.S.-supported programs.

No patient-level prescribing or treatment regimen is provided. The article discusses policy questions involving HIV programs, country health systems, and access to health products.

Clinical Best Practices

• The article identifies data and transparency as important for monitoring services, programs, and health outcomes.
• It raises responsible transition and sustainability planning, supported by appropriate early-warning indicators, metrics, and monitoring systems, as policy questions.
• It identifies reaching populations facing the greatest vulnerability and risk as a consideration when countries assume greater responsibility for financing and service delivery.

Related Resources & Content